METOSINAT 47.5 mg depottabletti Finland - Finland - Fimea (Suomen lääkevirasto)

metosinat 47.5 mg depottabletti

hexal ag - metoprololi succinas - depottabletti - 47.5 mg - metoprololi

METOSINAT 95 mg depottabletti Finland - Finland - Fimea (Suomen lääkevirasto)

metosinat 95 mg depottabletti

hexal ag - metoprololi succinas - depottabletti - 95 mg - metoprololi

METOSINAT 142.5 mg depottabletti Finland - Finland - Fimea (Suomen lääkevirasto)

metosinat 142.5 mg depottabletti

hexal ag - metoprololi succinas - depottabletti - 142.5 mg - metoprololi

METOSINAT 190 mg depottabletti Finland - Finland - Fimea (Suomen lääkevirasto)

metosinat 190 mg depottabletti

hexal ag - metoprololi succinas - depottabletti - 190 mg - metoprololi

OMNIPAQUE 200 mg I/ml injektioneste, liuos Finland - Finland - Fimea (Suomen lääkevirasto)

omnipaque 200 mg i/ml injektioneste, liuos

amersham health as - iohexolum - injektioneste, liuos - 200 mg i/ml - joheksoli

NUMETA G13E infuusioneste, emulsio Finland - Finland - Fimea (Suomen lääkevirasto)

numeta g13e infuusioneste, emulsio

baxter oy - argininum,magnesii acetas tetrahydricum,natrii chloridum,methioninum,leucinum,acidum asparticum,soiae oleum raffinatum,alaninum,cysteinum,acidum glutamicum,threoninum,olivae oleum raffinatum,tyrosinum,natrii glycerophosphas hydricus,serinum,lysini monohydricum,taurinum,phenylalaninum,acidum aminoaceticum,valinum,tryptophanum,isoleucinum,histidinum,ornithini hydrochloridum,kalii acetas,glucosum monohydricum,prolinum,calcii chloridum dihydricum - infuusioneste, emulsio - yhdistelmävalmisteet

Flavamed 6 mg/ml oraaliliuos Finland - Finland - Fimea (Suomen lääkevirasto)

flavamed 6 mg/ml oraaliliuos

berlin-chemie ag - ambroxol hydrochloride - oraaliliuos - 6 mg/ml - ambroksoli

Scopoderm 1 mg / 72 tuntia depotlaastari Finland - Finland - Fimea (Suomen lääkevirasto)

scopoderm 1 mg / 72 tuntia depotlaastari

baxter oy - scopolamine - depotlaastari - 1 mg / 72 tuntia - skopolamiini

Laktufarm 670 mg/ml oraaliliuos Finland - Finland - Fimea (Suomen lääkevirasto)

laktufarm 670 mg/ml oraaliliuos

orifarm healthcare a/s - lactulose solution - oraaliliuos - 670 mg/ml - laktuloosi

Blincyto Kesatuan Eropah - Finland - EMA (European Medicines Agency)

blincyto

amgen europe b.v. - blinatumomab - prekursorisolujen lymfoblastinen leukemia-lymfooma - antineoplastiset aineet - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.